DEXCOM INC Income Taxes Disclosure
7. Income Taxes | ||||||||||||||
| Twelve Months Ended December 31, | |||||||||||||||||
| (In millions) | 2025 | 2024 | 2023 | ||||||||||||||
| United States | $ | 961.4 | $ | 659.8 | $ | 732.4 | |||||||||||
| Outside of the United States | 127.0 | 49.2 | (22.0) | ||||||||||||||
| Total | $ | 1,088.4 | $ | 709.0 | $ | 710.4 | |||||||||||
| Twelve Months Ended December 31, | |||||||||||||||||
| (In millions) | 2025 | 2024 | 2023 | ||||||||||||||
| Current: | |||||||||||||||||
| Federal | $ | 37.1 | $ | 157.4 | $ | 149.1 | |||||||||||
| State | 7.1 | 16.5 | 18.1 | ||||||||||||||
| Foreign | 25.7 | 2.7 | 56.7 | ||||||||||||||
| Total current income taxes | 69.9 | 176.6 | 223.9 | ||||||||||||||
| Deferred: | |||||||||||||||||
| Federal | 169.7 | (55.2) | (93.7) | ||||||||||||||
| State | 16.0 | (2.0) | 14.6 | ||||||||||||||
| Foreign | (3.5) | 13.4 | 24.1 | ||||||||||||||
| Total deferred income taxes | 182.2 | (43.8) | (55.0) | ||||||||||||||
| Total | $ | 252.1 | $ | 132.8 | $ | 168.9 | |||||||||||
| Twelve Months Ended December 31, | |||||
| (In millions) | 2025 | ||||
Federal | $ | 68.0 | |||
State | 10.6 | ||||
Foreign | 15.8 | ||||
Total | $ | 94.4 | |||
| December 31, | Year of Expiration | ||||||||||||||||
| (In millions) | 2025 | 2024 | |||||||||||||||
| Net operating loss: | |||||||||||||||||
| Federal | $ | 3.8 | $ | 12.1 | 2028 | ||||||||||||
| California | 162.0 | 162.0 | 2037 | ||||||||||||||
| Other states | 5.1 | 5.8 | 2028 | ||||||||||||||
| Tax credits: | |||||||||||||||||
| Federal | |||||||||||||||||
| Foreign tax credits | 1.2 | 0.1 | 2032 | ||||||||||||||
| California R&D credits | 134.6 | 124.9 | Indefinite | ||||||||||||||
| California AMT Credits | $ | 0.5 | $ | 0.5 | Indefinite | ||||||||||||
| December 31, | |||||||||||
| (In millions) | 2025 | 2024 | |||||||||
| Deferred tax assets: | |||||||||||
| Net operating loss carryforwards | $ | 12.6 | $ | 14.4 | |||||||
| Capitalized research and development expenses | 103.6 | 265.0 | |||||||||
| Tax credits | 85.6 | 79.2 | |||||||||
| Share-based compensation | 20.6 | 22.5 | |||||||||
| Fixed and intangible assets | 187.3 | 263.6 | |||||||||
| Accrued liabilities and reserves | 86.8 | 87.4 | |||||||||
| Convertible debt | 11.3 | 16.0 | |||||||||
| Total gross deferred tax assets | 507.8 | 748.1 | |||||||||
| Less: valuation allowance | (160.7) | (221.9) | |||||||||
| Total net deferred tax assets | 347.1 | 526.2 | |||||||||
| Deferred tax liabilities: | |||||||||||
| Fixed assets and acquired intangibles assets | (45.8) | (59.3) | |||||||||
Net unrealized gain on equity investments | (18.4) | — | |||||||||
| Other | — | (0.3) | |||||||||
| Total deferred tax liabilities | (64.2) | (59.6) | |||||||||
| Net deferred tax assets (liabilities) | $ | 282.9 | $ | 466.6 | |||||||
| Twelve Months Ended December 31, | |||||||||||
| (In millions) | 2025 | ||||||||||
| U.S. Federal Statutory Rate | $ | 228.6 | 21.0 | % | |||||||
| Increase (Decrease) Resulting From: | |||||||||||
| State and Local Income Tax, Net of Federal Income Tax Effect | 16.4 | 1.5 | % | ||||||||
| Foreign Tax Effects | |||||||||||
Ireland | |||||||||||
Change in Rate | 63.6 | 5.8 | % | ||||||||
Change in Valuation Allowance | (74.5) | (6.8) | % | ||||||||
| Other | 5.8 | 0.5 | % | ||||||||
Malaysia | |||||||||||
Foreign rate differential | (14.8) | (1.4) | % | ||||||||
Other | 8.9 | 0.8 | % | ||||||||
Other foreign jurisdictions | 6.7 | 0.6 | % | ||||||||
Effect of Cross-Border Taxes | 3.0 | 0.3 | % | ||||||||
| Tax Credits | |||||||||||
Research and development credits | (13.6) | (1.2) | % | ||||||||
| Changes in Valuation Allowance | 0.4 | — | % | ||||||||
| Nontaxable or Nondeductible Items | |||||||||||
| Stock and officers compensation | 16.1 | 1.5 | % | ||||||||
| Other | 2.5 | 0.2 | % | ||||||||
| Changes in Unrecognized Tax Benefits | 4.4 | 0.4 | % | ||||||||
| Other | (1.4) | (0.1) | % | ||||||||
| Total | $ | 252.1 | 23.2 | % | |||||||
| Twelve Months Ended December 31, | ||||||||||||||
| (In millions) | 2024 | 2023 | ||||||||||||
| U.S. federal statutory tax rate | $ | 148.9 | $ | 149.2 | ||||||||||
| State income tax, net of federal benefit | 10.2 | 7.8 | ||||||||||||
| Permanent items | 10.5 | (2.7) | ||||||||||||
| Research and development credits | (24.6) | (28.3) | ||||||||||||
| Foreign tax credit | (1.2) | — | ||||||||||||
| Foreign rate differential | 1.6 | 15.8 | ||||||||||||
| Stock and officers compensation | 3.8 | 5.6 | ||||||||||||
| Collaboration agreement milestone share-based payment | (32.2) | (72.1) | ||||||||||||
| Change in statutory tax rates | 51.5 | 19.4 | ||||||||||||
| Intellectual property transfer | — | 63.9 | ||||||||||||
| Other | 6.7 | 0.3 | ||||||||||||
| Change in valuation allowance | (42.4) | 10.0 | ||||||||||||
| Income taxes at effective rates | $ | 132.8 | $ | 168.9 | ||||||||||
| (In millions) | |||||
Balance at January 1, 2023 | $ | 52.0 | |||
Increases related to prior year tax positions | 0.8 | ||||
Increases related to current year tax positions | 6.6 | ||||
| Balance at December 31, 2023 | 59.4 | ||||
Increases related to prior year tax positions | 0.1 | ||||
Increases related to current year tax positions | 6.7 | ||||
| Balance at December 31, 2024 | 66.2 | ||||
Increases related to prior year tax positions | 0.2 | ||||
Increases related to current year tax positions | 5.7 | ||||
Decreases related to prior year tax positions | (3.0) | ||||
| Balance at December 31, 2025 | $ | 69.1 | |||
| Jurisdiction | Fiscal Year | ||||
| United States (Federal and state) | 2007 - 2025 | ||||
| United Kingdom | 2022 - 2025 | ||||
| Malaysia | 2020 - 2025 | ||||
| Ireland | 2023 - 2025 | ||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 12, 2026 | Showing above |
| 2024 | Feb 18, 2025 | |
| 2023 | Feb 8, 2024 | |
| 2022 | Feb 9, 2023 | |
| 2021 | Feb 14, 2022 | |
| 2020 | Feb 11, 2021 | |
| 2019 | Feb 13, 2020 | |
| 2018 | Feb 21, 2019 | |
| 2017 | Feb 27, 2018 | |
| 2016 | Feb 28, 2017 | |
| 2015 | Feb 23, 2016 | |
About Income Taxes Disclosures
The income tax disclosure reveals how much a company actually pays in taxes versus what the statutory rate would predict. Analysts focus on the effective tax rate (ETR) reconciliation, which breaks down every item driving the gap between the 21% federal rate and the company's reported ETR — including R&D credits, foreign rate differentials, and state taxes. Deferred tax assets (DTAs) and their valuation allowances signal management's confidence in future profitability: a rising allowance suggests the company doubts it can use accumulated tax benefits. Uncertain tax benefit (UTB) reserves quantify exposure to IRS challenges on aggressive positions.
Key signals to watch: sudden ETR drops without clear operational reasons, large increases in valuation allowances, growing UTB balances, and significant unremitted foreign earnings. Post-TCJA, pay attention to GILTI and BEAT provisions that affect multinational tax structures. Compare the cash taxes paid (from the cash flow statement) against the income tax provision to gauge earnings quality.